SCHEMBL6869489

SCHEMBL6869489

COC(=O)Cc1cc(Cl)ccc1C1=CCN(C(=O)O)CC1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.41
TRPV1 Q8NER1 1/20 0.40
CNR1 P21554 2/20 0.39
LMNA P02545 3/20 0.39
KDM4E B2RXH2 1/20 0.39
MAPK1 P28482 1/20 0.38
CCR1 P32246 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
HTT P42858 2/20 0.37
NPSR1 Q6W5P4 1/20 0.37
KIT P10721 1/20 0.37
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
PPARG P37231 1/20 0.36
PPARA Q07869 1/20 0.36
HCRTR1 O43613 1/20 0.36
HCRTR2 O43614 1/20 0.36
QDPR P09417 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5226078 0.86 PDK4 (0.52) CNR1
SCHEMBL27842059 0.82 CNR1 (0.43) MAPTCNR1LMNAKDM4ECCR1
SCHEMBL4433323 0.81 MAPT (0.52) MAPTCNR1LMNAKDM4ECCR1
SCHEMBL6870916 0.77 CCR1 (0.41) MAPTCNR1LMNAKDM4ECCR1
SCHEMBL27598375 0.76 HTR2C (0.46) MAPTKDM4EMAPK1KMT2AMEN1
SCHEMBL28352494 0.75 MEN1 (0.43) MAPTTDP1KMT2AMEN1ALDH1A1
SCHEMBL17397740 0.75 TDP1 (0.41) MAPTKDM4ETDP1NPSR1ALDH1A1
SCHEMBL6869073 0.74 CNR1 (0.42) MAPTTRPV1CNR1LMNAKDM4E
SCHEMBL22324861 0.73 FASN (0.43) MAPTLMNAKDM4EMAPK1TDP1
SCHEMBL28510941 0.73 CNR1 (0.40) MAPTCNR1LMNAKDM4ECCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6818658-B2 TREATING OBESITY, DIABETES, SEXUAL DYSFUNCTION, INCLUDING ERECTILE DYSFUNCTION AND FEMALE SEXUAL DYSFUNCTION. MERCK & CO., INC. 2004-11-16 US disclosed
US-20030225060-A1 Acylated piperidine derivatives as melanocortin-4 receptor agonists MERCK SHARP & DOHME CORP. 2003-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225060-A1 Acylated piperidine derivatives as melanocortin-4 receptor agonists MC4R, MC5R, MC3R MAPT 3060/4885TRPV1 318/4885CNR1 229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.